We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

103 hedge funds and large institutions have $108M invested in Praxis Precision Medicines in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 40 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $95.6M → $108M (+$12.2M)

0.26% more ownership

Funds ownership: 6.16% → 6.43% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 108 → 103 (-5)

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

35% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 40

Holders
103
Holders Change
-5
Holders Change %
-4.63%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
26
Reduced
40
Closed
23
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$537K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$3.81M
2
KCM
Kingdon Capital Management
New York
+$3.53M
3
Bank of America
Bank of America
North Carolina
+$3.08M
4
OCA
Octagon Capital Advisors
New York
+$1.66M
5
Verition Fund Management
Verition Fund Management
Connecticut
+$1.59M

Top Sellers

1
VVA
Vida Ventures Advisors
Massachusetts
-$3.06M
2
Millennium Management
Millennium Management
New York
-$1.69M
3
PHS
PFM Health Sciences
California
-$1.42M
4
GCM
Graham Capital Management
Connecticut
-$1.06M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$926K
Name Holding Trade Value Shares
Change 		Change in
Stake
CIBC Asset Management
26
CIBC Asset Management
Ontario, Canada
$904K +$789K +25,309 New
Federated Hermes
27
Federated Hermes
Pennsylvania
$877K +$592K +18,997 +341%
Renaissance Technologies
28
Renaissance Technologies
New York
$866K -$177K -5,674 -19%
Northern Trust
29
Northern Trust
Illinois
$837K -$38.9K -1,248 -5%
Man Group
30
Man Group
United Kingdom
$730K +$140K +4,480 +28%
Two Sigma Investments
31
Two Sigma Investments
New York
$663K -$339K -10,881 -37%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$600K -$31.2K -1,002 -6%
LCM
33
Laurion Capital Management
New York
$468K -$2.99K -96 -0.7%
N
34
Nuveen
North Carolina
$455K -$10.5K -338 -3%
Morgan Stanley
35
Morgan Stanley
New York
$433K -$193K -6,188 -34%
Millennium Management
36
Millennium Management
New York
$398K -$1.69M -54,325 -83%
AQR Capital Management
37
AQR Capital Management
Connecticut
$382K -$190K -6,081 -36%
IC
38
Ikarian Capital
Texas
$357K +$312K +10,000 New
XT
39
XTX Topco
Cayman Islands
$352K +$29.3K +941 +11%
Los Angeles Capital Management
40
Los Angeles Capital Management
California
$315K +$54.5K +1,748 +25%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$283K – – –
RJA
42
Raymond James & Associates
Florida
$275K -$4.15K -133 -2%
BCM
43
Bridgeway Capital Management
Texas
$270K – – –
Charles Schwab
44
Charles Schwab
California
$263K +$54.5K +1,746 +31%
HF
45
HRT Financial
New York
$251K -$200K -6,404 -48%
Point72 Asset Management
46
Point72 Asset Management
Connecticut
$238K – – –
SCM
47
Silverarc Capital Management
Massachusetts
$234K -$3.31K -106 -2%
AllianceBernstein
48
AllianceBernstein
Tennessee
$192K +$35.6K +1,140 +27%
TCM
49
Tekla Capital Management
Massachusetts
$179K – – –
CIC
50
Cornercap Investment Counsel
Georgia
$174K +$468 +15 +0.3%
1
2
3 4 5

PRAX Hedge Fund Activity: Q4 2022 in Review

103 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2022, worth a combined $108M — up 13% from $95.6M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of PRAX and 18 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 26 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.81M. The largest seller was Vida Ventures Advisors, cutting an estimated $3.06M.

  • 103 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2022, down from 108 in Q3 2022.
  • Funds reported $108M of Praxis Precision Medicines stock for Q4 2022, up 13% quarter-over-quarter.
  • 18 funds opened new Praxis Precision Medicines positions in Q4 2022 and 23 closed out, a net change of -5 holders.
  • The largest Praxis Precision Medicines buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.81M added.
  • The largest Praxis Precision Medicines seller in Q4 2022 was Vida Ventures Advisors, an estimated $3.06M sold.

Based on aggregated 13F filings for Q4 2022.